Cargando…
Healthcare Professional (HCP) and Patient Usability Evaluation and Preferences of Two Auto-injector Devices for Self-Injection of Biosimilars, SB4 and SB5: A Literature Review
BACKGROUND: Numerous biologic drugs, including etanercept and adalimumab, are administered subcutaneously. This study reviewed the evidence on the usability and preference of self-injection devices of SB4 and SB5 compared with the reference product injectors. METHODS: A systematic search was conduct...
Autores principales: | Corominas, Héctor, Young, David, Cummings, J. R. Fraser, Bouhnik, Yoram, Armuzzi, Alessandro, Thaci, Diamant, Kim, Jihyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480234/ https://www.ncbi.nlm.nih.gov/pubmed/37615857 http://dx.doi.org/10.1007/s40261-023-01284-5 |
Ejemplares similares
-
Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE study
por: Fautrel, Bruno, et al.
Publicado: (2023) -
PERFUSE: Non-Interventional Cohort Study of Patients Receiving Infliximab Biosimilar SB2: Results in Pediatric Patients
por: Martinez-Vinson, Christine, et al.
Publicado: (2022) -
SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020) -
Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
por: Ebbers, Hans C., et al.
Publicado: (2020) -
Correction to: SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)